Quarry LP’s Cardiff Oncology CRDF Stock Holding History

Quarry LP’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,135	Closed	-$22.9K	–	2224
2025 Q3	$22.9K	Buy	+11,135	New	+$30.8K	0.01%	1317

Other funds holding CRDF

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Quarry LP's CRDF Position: Q4 2025 in Review

Quarry LP sold out of Cardiff Oncology (CRDF) in Q4 2025, closing a stake of 11,135 shares — an estimated $22.9K sold.

Quarry LP first reported a position in CRDF in Q3 2025 and held it in 1 quarter. The position peaked at $22.9K in Q3 2025. 110 funds tracked by Wall St. Rank hold CRDF as of Q4 2025.

Quarry LP reported no remaining Cardiff Oncology position as of Q4 2025 after selling out during the quarter.
Quarry LP sold 11,135 Cardiff Oncology shares in Q4 2025, an estimated $22.9K.
Quarry LP first reported a position in Cardiff Oncology in Q3 2025 and held it in 1 quarter.
Quarry LP's Cardiff Oncology position peaked at $22.9K in Q3 2025.
110 funds tracked by Wall St. Rank held Cardiff Oncology as of Q4 2025.

Based on Quarry LP's 13F filing for Q4 2025, filed 13 Feb 2026.